分享的新抗原图谱用于现成的癌症疫苗开发
Angela Mauriello1, Beatrice Cavalluzzo1, Concetta Ragone1
1Innovative Immunological Models Unit, Istituto Nazionale Tumori IRCCS - "Fond G. Pascale", Via Mariano Semmola, 52, Naples, Italy.
Journal of translational medicine
|May 19, 2025
概括
这项研究确定了跨常见癌症突变的共享突变新抗原 (SNV和InDel-NeoAgs). 这些新抗原对于为广泛的患者群体开发"现成"癌症疫苗至关重要.
科学领域:
- 免疫基因组学是什么
- 癌症免疫学 癌症免疫学
- 疫苗的研发工作正在进行中.
背景情况:
- 常见的癌症突变产生共享的新抗原 (SNV和InDel-NeoAgs).
- 之前的研究已经确定了这些与特定的HLA-A和HLA-B单元型相关的新抗原.
研究的目的:
- 将共享的新抗原的分析扩展到更广泛的MHC I类单元类型.
- 通过多个HLA位点的流行癌症突变识别可向的新抗原.
主要方法:
- 分析了50个MHC I类哈普洛类型 (10个HLA-A,27个HLA-B,13个HLA-C).
- 包括在至少5%的癌症患者中发现的突变蛋白.
- 对野生类型 (wt) 蛋白质的新抗原亲和度改善的评估.
主要成果:
- 鉴定了15个SNV-NeoAgs和55个InDel-NeoAgs,显著改善了亲和力.
- PIK3CAH1047R和LARP4BT163Hfs分别是SNV-NeoAgs和InDel-NeoAgs的主要来源.
- HLA-A*33:03和HLA-B*58:01分别与SNV-NeoAgs和InDel-NeoAgs的数量最高相关.
结论:
- 这项研究提供了第一个共享突变新抗原的全面目录.
- 这些新抗原对于开发"现成"癌症疫苗至关重要.
- 针对这些新抗原的疫苗可以使全球大量癌症患者受益.
更多相关视频
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
9.4K
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.1K
相关概念视频
Cancer Vaccines
321
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
321
Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Antigens Involved in Adaptive Immunity
434
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
434
